¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"large cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • lacunar cell
    °ø°£¼¼Æ÷
  • mitotic cell
    À¯»çºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • motor cell
    ¿îµ¿½Å°æ¼¼Æ÷
  • mucous cell
    Á¡¾×¼¼Æ÷
  • mulberry cell
    ¿Àµð¼¼Æ÷
  • multinuclear giant cell
    ´ÙÇÙ°Å´ë¼¼Æ÷, ¹µÇÙ°Å´ë¼¼Æ÷
  • multipolar nerve cell
    ´Ù±Ø½Å°æ¼¼Æ÷, ¹µ±Ø½Å°æ¼¼Æ÷
  • myeloid cell
    °ñ¼ö¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
  • paralutein cell
    ȲüÁÖÀ§¼¼Æ÷, ºÎȲü¼¼Æ÷
  • parietal cell
    º®¼¼Æ÷
  • pathologic cell
    º´Àû¼¼Æ÷
  • perivascular cell
    Ç÷°üÁÖÀ§¼¼Æ÷
  • phagocytic cell
    Æ÷½Ä¼¼Æ÷
  • pheochrome cell
    ºÎ½Åģũ·Ò¼¼Æ÷
  • photoreceptor cell
    (¢¡visual cell) ½Ã°¢¼¼Æ÷
  • physaliphorous cell
    ´ã°øÆ÷¼¼Æ÷
  • pigment cell
    »ö¼Ò¼¼Æ÷
  • pillar cell
    ±âµÕ¼¼Æ÷
  • pilomotor cell
    Åп½Å°æ¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • pluripotential cell
    ´Ù´É¼º¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • horny cell
    °¢Áú¼¼Æ÷
  • huma immunodeficiency virus,follicular dendritic cell infection by
    ¿©Æ÷»ó¼öÁö¼¼Æ÷°¨¿°
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T-cell lymphotrophic virus
    Àΰ£ T¼¼Æ÷ ¸²ÇÁ ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hybrid cell
    ÇÏÀ̺긮µå¼¼Æ÷
  • hybridoma, B cell
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hybridoma, T cell
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hypercomplex cell
    Ãʺ¹ÇÕ¼¼Æ÷(õ±ÜÜùêá¬øà)
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, cell-mediated
    ¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • cell mediated reaction
    ¼¼Æ÷¸Å°³¼º ¹ÝÀÀ.
  • cell membrane
    ¼¼Æ÷¸·
  • cell membrane
    ¼¼Æ÷¸·(á¬øàØ¯)
  • cell membrane
    ¼¼Æ÷¸·
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º(á¬øàØ¯÷âΦàõ).
  • cell migration disorder
  • cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
  • cell of reticulum
    ¹úÁýÀ§Ä­
  • cell organelles
    ¼¼Æ÷¼Ò±â°ü
  • cell permeability
    ¼¼Æ÷Åõ°ú¼º
  • cell physiology
    ¼¼Æ÷»ý¸®ÇÐ
  • cell pole
    ¼¼Æ÷±Ø(á¬øàп)
  • cell pole
    ¼¼Æ÷±Ø(á¬øàп).
  • cell proliferation
    ¼¼Æ÷ Áõ½Ä
  • cell respiration
    ¼¼Æ÷È£Èí
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
FDC factor-dependent cell [line]; follicular dendritic cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
B-CLL B cell Type
B-ALL B cell acute lymphoblastic leukemia
BCR B cell antigen receptor
B CLL B cell chronic lymphocytic leukemia
BCDF B cell differentiation factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nociceptive-specific cell
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷, À¯ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷
  • non-caseating epithelioid cell granulomata
    ºñ°Ç¶ô¼º À¯»óÇÇ ¼¼Æ÷ À°¾ÆÁ¾
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-nociceptive cell
    ºñÄ§ÇØ ¼ö¿ë¼º ¼¼Æ÷, ºñÀ¯ÇØ ¼ö¿ë¼º ¼¼Æ÷
  • null cell
    ´­ ¼¼Æ÷
    B, T ¼¼Æ÷ Ç¥¸é Ç¥Áö¸¦ °¡ÁöÁö ¾ÊÀº ¸²ÇÁ±¸.
  • off-cell pause
    ²¨Áü ¼¼Æ÷ ÁßÁö
  • on-cell
    ÄÑÁü ¼¼Æ÷
  • osteoprogenitor cell
    °ñ Á¶»ó ¼¼Æ÷, »À Á¶»ó ¼¼Æ÷
    1. °ñÀÇ À¯¸® Ç¥¸é ȤÀº ±× ±Ùó¿¡¼­ º¼ ¼ö ÀÖ´Â ºñ±³Àû ¹ÌºÐÈ­µÈ ¼¼Æ÷·Î¼­, ¾î¶² ȯ°æ¿¡¼­´Â ¼¼Æ÷ ºÐ¿­ÇÏ¿© °ñ¾Æ¼¼Æ÷·Î ÀüȯµÇµç°¡ ȤÀº À¶ÇÕÇÏ¿© ÆÄ°ñ ¼¼Æ÷·Î µÇ±âµµ ÇÑ´Ù. 2. ÀÏ¹Ý °ÉÇÕ Á¶Á÷ÀÇ ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î °£Áú Á¶Á÷¿¡¼­ À¯·¡ÇÑ ¼¼Æ÷·Î¼­ À¯»ç ºÐ¿­ ´É·Â°ú »À ¼¼Æ÷·Î ºÐÈ­µÉ ¼ö ÀÖ´Â ´É·ÂÀ» °®°í ÀÖ´Ù. Áß°£¿± ¼¼Æ÷¿Í À¯»çÇϸç, ÇÙÀº ¿°±â¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÇ°í ¼¼Æ÷ÁúÀº ¾çÀÌ Àû¾î »ê¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÈ´Ù.
  • oxyntic cell
    »ê ºÐºñ¼º ¼¼Æ÷
    »ê ºÐºñ¼ºÀÇ À§º® ¼¼Æ÷¿Í °°ÀÌ »êÀ» ºÐºñÇÏ´Â ¼¼Æ÷.
  • oxyphil cell
    È£»ê¼º ¼¼Æ÷
  • oxyphilic cell
    È£»ê ¼¼Æ÷, È£»ê¼º ¼¼Æ÷
  • packed cell volume
    ÃæÀü ¼¼Æ÷ ¿ëÀû
  • packed red blood cell
    ³óÃà ÀûÇ÷±¸, ÃæÀü ÀûÇ÷±¸
    1. Ç÷¾×À» ¿ø½É ºÐ¸®ÇßÀ» ¶§ ¹Ù´Ú¿¡ ¹ÐÁýÇØ ÀÖ´Â °Í, ÃæÀü ÀûÇ÷±¸ ºÎÇǸ¦ Ç츶ÅäÅ©¸®Æ®¶óÇÑ´Ù. 2. hematocrit °ü¿¡ äÃëÇÑ ÀüÇ÷À» ÃÖ´ë·Î ¿ø½É ºÐ¸®ÇÏ¿© ¾ò¾îÁö´Â ÀûÇ÷±¸ÀÇ Ä§ÀüÃþ.
  • paneth cell
    È£»ê¼º °ú¸³ ¼¼Æ÷
  • papillary squamous cell carcinoma
    À¯µÎ»ó ÆíÆò »óÇÇ ¼¼Æ÷¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
virus-transformed cell A cell that has been genetically changed to a tumour cell, the change being subsequently tramsmitted to all descendent cell's; cell's transformed by oncornaviruses continue to produce virus in high concentration without being killed; DNA tumour virus-transformed cell's develop (along with other changes) tumour-associated antigens and rarely produce virus.
(05 Mar 2000)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
glomerulosa cell A cell of the zona glomerulosa of the adrenal cortex that is the source of aldosterone; the cell's are arranged in spherical or oval groups.
(05 Mar 2000)
cell <cell biology> An autonomous self replicating unit (in principle) that may constitute an organism (in the case of unicellular organisms) or be a sub unit of multicellular organisms in which individual cells may be more or less specialised differentiated) for particular functions.
The individual units from which tissues of the body are formed. All living organisms are composed of one or more cells.
(26 Mar 1998)
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
cell aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type.
(12 Dec 1998)
cell aging The decrease in the cell's ability to proliferate with the passing of time. Each cell is programmed for a certain number of cell divisions and at the end of that time proliferation halts. The cell enters a quiescent state after which it experiences cell death via the process of apoptosis.
(12 Dec 1998)
cell behaviour <cell biology> General term for activities of whole cells such as movement, adhesion and proliferation, by analogy with animal behaviour.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á